Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altheus Therapeutics Inc.

www.altheustherapeutics.com

Latest From Bentley Pharmaceuticals Inc.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was more than twice that of Q2 with 105 deals bringing in over $4.4 billion, but not one IPO to be found. M&A dollars also nearly doubled to $23 billion in the third quarter--versus the previous three months--and of the 26 transactions with known values, more than half were over $100 million. Alliances saw activity focused primarily in two areas: drug delivery and large molecules, each category with 16 deals apiece. Total potential deal value (for the 43 alliances with known values) reached $4.5 billion, over one and a half times that of the previous quarter.
BioPharmaceutical

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
BioPharmaceutical

Valuing Marketed Products

Wecompare an industry formula to valuing the acquisiton of marketed products to actual deals signed since 2000.
BioPharmaceutical

OptiNose AS

OptiNose's founders hope that their bi-directional nasal delivery system could overcome most of the distribution and absorption problems associated with traditional spray pump devices.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Altheus Therapeutics Inc.
  • Senior Management
  • Dennis Schafer, Pres. & CEO
  • Contact Info
  • Altheus Therapeutics Inc.
    Phone: (405) 319-8180
    755 Research Pkwy.
    Ste. 435
    Oklahoma City, OK 73104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register